RxDoctor Payments Data

Christopher Hamm, MD

Internal Medicine · Des Peres, MONPI 1730490830

Payments from drug & device makers

$328in general payments, 2019–2025

Across 13 payments — averaging $25.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mannkind Corporation$119
  • Lilly USA, LLC$54
  • AbbVie$44
  • GSK$38
  • Novo Nordisk$36
  • Abbott$23
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$20964%
  • Gifts$11936%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Mannkind Corporation2$119
Lilly USA, LLC3$54
AbbVie2$44
GSK2$38
Novo Nordisk2$36
Abbott1$23
Pfizer1$15

How this compares

$328 in reported general payments places this provider in the 55th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$198,876
Medicare patients
468
Services billed
2,077

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban345$411,833
JardianceEmpagliflozin75$96,814
JanuviaSitagliptin Phosphate80$85,321
OzempicSemaglutide48$81,237
XareltoRivaroxaban42$56,860
OxycontinOxycodone Hcl77$55,027
MounjaroTirzepatide27$45,739
TrulicityDulaglutide25$44,058
FarxigaDapagliflozin Propanediol34$42,867
Breo ElliptaFluticasone/Vilanterol77$38,606
MyrbetriqMirabegron32$34,538
EntrestoSacubitril/Valsartan29$33,857
TradjentaLinagliptin29$31,635
Repatha SureclickEvolocumab24$25,938
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$25,641

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$15$416,519362 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta, Arexvy$38$95,291191 claims
Lilly USA, LLCMounjaro, Trulicity$54$89,79752 claims
Novo NordiskOzempic$36$81,23748 claims
AbbVieSynthroid$44$4,95553 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Des Peres

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →